A systematic review of osteoporosis medication adherence and osteoporosis-related fracture costs in men

Applied Health Economics and Health Policy

Volumn 12, Issue 3, 2014, Pages 267-277

  Mikyas, Yeshi ^a   Agodoa, Irene ^a   Yurgin, Nicole ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT;

EMBASE; FRAGILITY FRACTURE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HIP FRACTURE; HUMAN; MEDICATION COMPLIANCE; MEDLINE; OSTEOPOROSIS; REVIEW; TREATMENT OUTCOME; DRUG COST; ECONOMICS; FRACTURES, BONE; HEALTH CARE DELIVERY; MALE; RISK FACTOR; STATISTICS AND NUMERICAL DATA; UTILIZATION;

BONE DENSITY CONSERVATION AGENTS; DELIVERY OF HEALTH CARE; DIPHOSPHONATES; DRUG COSTS; FRACTURES, BONE; HEALTH CARE COSTS; HUMANS; MALE; MEDICATION ADHERENCE; OSTEOPOROSIS; RISK FACTORS;

EID: 84901654164     PISSN: 11755652     EISSN: 11791896     Source Type: Journal    
DOI: 10.1007/s40258-013-0078-1     Document Type: Review

References (78)

1. WHO Technical Report Series 921. Report of a WHO Scientific Group (2003). Prevention and management of osteoporosis. http://whqlibdoc.who.int/trs/who- trs-921.pdf. Accessed 9 Nov 2012.
2. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res. 2007;22(3):465-75. (Pubitemid 46797130)
3. Boonen S, Laan RF, Barton IP, Watts NB. Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies. Osteoporos Int. 2005;16(10):1291-8. (Pubitemid 41396959)
4. Strom O, Borgstrom F, Kanis JA, Compston J, Cooper C, McCloskey EV, et al. Osteoporosis: burden, health care provision and opportunities in the EU: a report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos. 2011;6(1-2):59-155.
5. Endo Y, Aharonoff GB, Zuckerman JD, Egol KA, Koval KJ. Gender differences in patients with hip fracture: a greater risk of morbidity and mortality in men. J Orthop Trauma. 2005;19(1):29-35. (Pubitemid 40309435)
6. Hawkes WG, Wehren L, Orwig D, Hebel JR, Magaziner J. Gender differences in functioning after hip fracture. J Gerontol A Biol Sci Med Sci. 2006;61(5):495-9. (Pubitemid 43794709)
7. Kannegaard PN, van der Mark S, Eiken P, Abrahamsen B. Excess mortality in men compared with women following a hip fracture. National analysis of comedications, comorbidity and survival. Age Ageing. 2010;39(2):203-9.
8. Kiebzak GM, Beinart GA, Perser K, Ambrose CG, Siff SJ, Heggeness MH. Undertreatment of osteoporosis in men with hip fracture. Arch Intern Med. 2002;162(19):2217-22. (Pubitemid 35231591)
9. Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med. 2000;343(9):604-10. (Pubitemid 30659471)
10. Reid DM, Adami S, Devogelaer JP, Chines AA. Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy. Calcif Tissue Int. 2001;69(4):242-7. (Pubitemid 33035397)
11. Sato Y, Iwamoto J, Kanoko T, Satoh K. Risedronate sodium therapy for prevention of hip fracture in men 65 years or older after stroke. Arch Intern Med. 2005;165(15):1743-8. (Pubitemid 41138962)
12. Orwoll E, Teglbjaerg CS, Langdahl BL, Chapurlat R, Czerwinski E, Kendler DL, et al. A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. J Clin Endocrinol Metab. 2012;97(9):3161-9.
13. Lekkerkerker F, Kanis JA, Alsayed N, Bouvenot G, Burlet N, Cahall D, et al. Adherence to treatment of osteoporosis: a need for study. Osteoporos Int. 2007;18(10):1311-7. (Pubitemid 47389473)
14. Kothawala P, Badamgarav E, Ryu S, Miller RM, Halbert RJ. Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc. 2007;82(12):1493-501. (Pubitemid 350211697)
15. Cramer JA, Gold DT, Silverman SL, Lewiecki EM. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int. 2007;18(8):1023-31. (Pubitemid 47019996)
16. The World Bank. Inflation, consumer prices (annual %). http://data.worldbank.org/indicator/FP.CPI.TOTL.ZG. Accessed 11 Sep 2013.
17. The World Bank. PPP conversion factor, GDP (LCU per international $). http://data.worldbank.org/indicator/PA.NUS.PPP/countries?page= 1&display=default. Accessed 11 Sep 2013.
18. Abhishek A, Pande I. Teriparatide in men: persistence and geographical variation in the UK. Osteoporos Int. 2009;20(8):1453-4.
19. Briesacher BA, Andrade SE, Fouayzi H, Chan KA. Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy. 2008;28(4):437-43. (Pubitemid 351466455)
20. Briesacher BA, Andrade SE, Harrold LR, Fouayzi H, Yood RA. Adoption of once-monthly oral bisphosphonates and the impact on adherence. Am J Med. 2010;123(3):275-80.
21. Cevikoi A, Umay E, Polat S, Ecerkale O, Cakci A. The relationship between bisphosphonate use and demographic characteristics of male osteoporosis patients. Clinics (Sao Paulo). 2011;66(4):579-82.
22. Curtis JR, Westfall AO, Cheng H, Lyles K, Saag KG, Delzell E. Benefit of adherence with bisphosphonates depends on age and fracture type: results from an analysis of 101,038 new bisphosphonate users. J Bone Miner Res. 2008;23(9):1435-41.
23. Devold HM, Furu K, Skurtveit S, Tverdal A, Falch JA, Sogaard AJ. Influence of socioeconomic factors on the adherence of alendronate treatment in incident users in Norway. Pharmacoepidemiol Drug Saf. 2012;21(3):297-304.
24. Gallagher AM, Rietbrock S, Olson M, van Staa TP. Fracture outcomes related to persistence and compliance with oral bisphosphonates. J Bone Miner Res. 2008;23(10):1569-75.
25. Hansen KE, Swenson ED, Baltz B, Schuna AA, Jones AN, Elliott ME. Adherence to alendronate in male veterans. Osteoporos Int. 2008;19(3):349-56. (Pubitemid 351199186)
26. Kamatari M, Koto S, Ozawa N, Urao C, Suzuki Y, Akasaka E, et al. Factors affecting long-term compliance of osteoporotic patients with bisphosphonate treatment and QOL assessment in actual practice: alendronate and risedronate. J Bone Miner Metab. 2007;25(5):302-9. (Pubitemid 47283269)
27. Kuo I, Ong C, Simmons L, Bliuc D, Eisman J, Center J. Successful direct intervention for osteoporosis in patients with minimal trauma fractures. Osteoporos Int. 2007;18(12):1633-9. (Pubitemid 47620315)
28. Lin TC, Yang CY, Yang YH, Lin SJ. Alendronate adherence and its impact on hip-fracture risk in patients with established osteoporosis in Taiwan. Clin Pharmacol Ther. 2011;90(1):109-16.
29. Netelenbos JC, Geusens PP, Ypma G, Buijs SJ. Adherence and profile of non-persistence in patients treated for osteoporosis: a large-scale, long-term retrospective study in The Netherlands. Osteoporos Int. 2011;22(5):1537-46.
30. Rietbrock S, Olson M, van Staa TP. The potential effects on fracture outcomes of improvements in persistence and compliance with bisphosphonates. QJM. 2009;102(1):35-42.
31. Ringe JD, Dorst A, Farahmand P. Comparing once yearly zoledronic acid with once weekly generic alendronate in the treatment of established male osteoporosis [abstract no. P840]. Osteoporos Int. 2010;21(Suppl 1):S357.
32. Roerholt C, Eiken P, Abrahamsen B. Initiation of anti-osteoporotic therapy in patients with recent fractures: a nationwide analysis of prescription rates and persistence. Osteoporos Int. 2009;20(2):299-307.
33. Vytrisalova M, Blazkova S. Exposure to osteoporosis medication in men [abstract no. PMS92]. Value Health. 2009;12(7):A450-51.
34. Wade SW, Curtis JR, Yu J, White J, Stolshek BS, Merinar C, et al. Medication adherence and fracture risk among patients on bisphosphonate therapy in a large United States health plan. Bone. 2012;50(4):870-5.
35. Sheehy O, Kindundu CM, Barbeau M, LeLorier J. Differences in persistence among different weekly oral bisphosphonate medications. Osteoporos Int. 2009;20(8):1369-76.
36. Borgstrom F, Sobocki P, Strom O, Jonsson B. The societal burden of osteoporosis in Sweden. Bone. 2007;40(6):1602-9. (Pubitemid 46766650)
37. Borgstrom F, Zethraeus N, Johnell O, Lidgren L, Ponzer S, Svensson O, et al. Costs and quality of life associated with osteoporosis-related fractures in Sweden. Osteoporos Int. 2006;17(5):637-50.
38. Konnopka A, Jerusel N, Konig HH. The health and economic consequences of osteopenia- and osteoporosis-attributable hip fractures in Germany: estimation for 2002 and projection until 2050. Osteoporos Int. 2009;20(7):1117-29.
39. Max W, Sinnot P, Kao C, Sung HY, Rice DP. The burden of osteoporosis in California, 1998. Osteoporos Int. 2002;13(6):493-500. (Pubitemid 34742209)
40. Rabenda V, Manette C, Lemmens R, Mariani AM, Struvay N, Reginster JY. The direct and indirect costs of the chronic management of osteoporosis: a prospective follow-up of 3440 active subjects. Osteoporos Int. 2006;17(9):1346-52. (Pubitemid 44127321)
41. Bass E, French DD, Bradham DD. A national perspective of Medicare expenditures for elderly veterans with hip fractures. J Am Med Dir Assoc. 2008;9(2):114-9.
42. Blume SW, Curtis JR. Medical costs of osteoporosis in the elderly Medicare population. Osteoporos Int. 2011;22(6):1835-44.
43. Burge RT, King AB, Balda E, Worley D. Methodology for estimating current and future burden of osteoporosis in state populations: application to Florida in 2000 through 2025. Value Health. 2003;6(5):574-83. (Pubitemid 37187720)
44. Christensen L, Iqbal S, Macarios D, Badamgarav E, Harley C. Cost of fractures commonly associated with osteoporosis in a managed-care population. J Med Econ. 2010;13(2):302-13.
45. Haussler B, Gothe H, Gol D, Glaeske G, Pientka L, Felsenberg D. Epidemiology, treatment and costs of osteoporosis in Germany-the BoneEVA Study. Osteoporos Int. 2007;18(1):77-84. (Pubitemid 44885498)
46. King AB, Tosteson AN, Wong JB, Solomon DH, Burge RT, Dawson-Hughes B. Interstate variation in the burden of fragility fractures. J Bone Miner Res. 2009;24(4):681-92.
47. Leslie WD, Metge CJ, Azimaee M, Lix LM, Finlayson GS, Morin SN, et al. Direct costs of fractures in Canada and trends 1996-2006: a population-based cost-of-illness analysis. J Bone Miner Res. 2011;26(10):2419-29.
48. Levy P, Levy E, Audran M, Cohen-Solal M, Fardellone P, Le Parc JM. The cost of osteoporosis in men: the French situation. Bone. 2002;30(4):631-6. (Pubitemid 34270503)
49. Melton LJ 3rd, Gabriel SE, Crowson CS, Tosteson AN, Johnell O, Kanis JA. Cost-equivalence of different osteoporotic fractures. Osteoporos Int. 2003;14(5):383-8. (Pubitemid 36919219)
50. Ohsfeldt RL, Borisov NN, Sheer RL. Fragility fracture-related direct medical costs in the first year following a nonvertebral fracture in a managed care setting. Osteoporos Int. 2006;17(2):252-8. (Pubitemid 43053589)
51. Pfister AK, Sale WG, Shaukat S. The economics of fragility fractures in West Virginia. W V Med J. 2009;105(4):10-3.
52. Strom O, Borgstrom F, Zethraeus N, Johnell O, Lidgren L, Ponzer S, et al. Long-term cost and effect on quality of life of osteoporosis-related fractures in Sweden. Acta Orthop. 2008;79(2):269-80. (Pubitemid 351878360)
53. Bouza C, Lopez T, Palma M, Amate JM. Hospitalised osteoporotic vertebral fractures in Spain: analysis of the national hospital discharge registry. Osteoporos Int. 2007;18(5):649-57. (Pubitemid 46525545)
54. Bubshait D, Sadat-Ali M. Economic implications of osteoporosis-related femoral fractures in Saudi Arabian society. Calcif Tissue Int. 2007;81(6):455-8.
55. Dai K, Zhang Q, Fan T, Sen SS. Estimation of resource utilization associated with osteoporotic hip fracture and level of postacute care in China. Curr Med Res Opin. 2007;23(12):2937-43.
56. Finnern HW, Sykes DP. The hospital cost of vertebral fractures in the EU: estimates using national datasets. Osteoporos Int. 2003;14(5):429-36. (Pubitemid 36919225)
57. Ganesan K, Pan D, Teklehaimenot S, Norris K. Racial differences in institutionalization after hip fractures: California hospital discharge data. Ethn Dis. 2005;15(4 Suppl 5):S5-30-3.
58. Gehlbach SH, Avrunin JS, Puleo E. Trends in hospital care for hip fractures. Osteoporos Int. 2007;18(5):585-91. (Pubitemid 46525536)
59. Gehlbach SH, Burge RT, Puleo E, Klar J. Hospital care of osteoporosis-related vertebral fractures. Osteoporos Int. 2003; 14(1):53-60. (Pubitemid 36267901)
60. Hepguler S, Cetin A, Deger C, Erkent U. Osteoporotic hip fracture costs in the elderly Turkish population. Acta Orthop Traumatol Turc. 2011;45(5):316-25.
61. Koeck CM, Schwappach DL, Niemann FM, Strassmann TJ, Ebner H, Klaushofer K. Incidence and costs of osteoporosis-associated hip fractures in Austria. Wien Klin Wochenschr. 2001;113(10):371-7. (Pubitemid 32479767)
62. Lee YH, Lim YW, Lam KS. Economic cost of osteoporotic hip fractures in Singapore. Singapore Med J. 2008;49(12):980-4.
63. Lippuner K, Golder M, Greiner R. Epidemiology and direct medical costs of osteoporotic fractures in men and women in Switzerland. Osteoporos Int. 2005;16(Suppl 2):S8-17.
64. Lippuner K, Grifone S, Schwenkglenks M, Schwab P, Popp AW, Senn C, et al. Comparative trends in hospitalizations for osteoporotic fractures and other frequent diseases between 2000 and 2008. Osteoporos Int. 2012;23(3):829-39.
65. Lonnroos E, Kautiainen H, Sund R, Karppi P, Hartikainen S, Kiviranta I, et al. Utilization of inpatient care before and after hip fracture: a population-based study. Osteoporos Int. 2009;20(6):879-86.
66. Lubbeke A, Stern R, Grab B, Herrmann F, Michel JP, Hoffmeyer P. Upper extremity fractures in the elderly: consequences on utilization of rehabilitation care. Aging Clin Exp Res. 2005;17(4):276-80. (Pubitemid 46190145)
67. Reginster JY, Gillet P, Ben Sedrine W, Brands G, Ethgen O, de Froidmont C, et al. Direct costs of hip fractures in patients over 60 years of age in Belgium. Pharmacoeconomics. 1999;15(5):507-14. (Pubitemid 29210953)
68. Russo A, Holmquist L, Elixhauser A. U.S. hospitalizations involving osteoporosis and injury, 2006. Health Cost Utilization Project Statistical Brief #76. http://www.hcup-us.ahrq.gov/reports/statbriefs/sb76.jsp.
69. Wiktorowicz ME, Goeree R, Papaioannou A, Adachi JD, Papadimitropoulos E. Economic implications of hip fracture: health service use, institutional care and cost in Canada. Osteoporos Int. 2001;12(4):271-8. (Pubitemid 34912733)
70. Song X, Shi N, Badamgarav E, Kallich J, Varker H, Lenhart G, et al. Cost burden of second fracture in the US health system. Bone. 2011;48(4):828-36.
71. Johnell O, Kanis JA, Jonsson B, Oden A, Johansson H, De Laet C. The burden of hospitalised fractures in Sweden. Osteoporos Int. 2005;16(2):222-8. (Pubitemid 40193212)
72. Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc. 2006;81(8):1013-22. (Pubitemid 44175011)
73. Imaz I, Zegarra P, Gonzalez-Enriquez J, Rubio B, Alcazar R, Amate JM. Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis. Osteoporos Int. 2010;21(11):1943-51.
74. Lo JC, Pressman AR, Omar MA, Ettinger B. Persistence with weekly alendronate therapy among postmenopausal women. Osteoporos Int. 2006;17(6):922-8. (Pubitemid 43781507)
75. Dell R, Greene D, Schelkun SR, Williams K. Osteoporosis disease management: the role of the orthopaedic surgeon. J Bone Joint Surgery Am. 2008;90(Suppl 4):188-94.
76. Harrington JT, Lease J. Osteoporosis disease management for fragility fracture patients: new understandings based on three years' experience with an osteoporosis care service. Arthritis Rheum. 2007;57(8):1502-6. (Pubitemid 350308850)
77. McLellan AR, Wolowacz SE, Zimovetz EA, Beard SM, Lock S, McCrink L, et al. Fracture liaison services for the evaluation and management of patients with osteoporotic fracture: a cost-effectiveness evaluation based on data collected over 8 years of service provision. Osteoporos Int. 2011;22(7):2083-98.
78. Newman ED, Ayoub WT, Starkey RH, Diehl JM, Wood GC. Osteoporosis disease management in a rural health care population: hip fracture reduction and reduced costs in postmenopausal women after 5 years. Osteoporos Int. 2003;14(2):146-51. (Pubitemid 40824231)